Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Treating p53-mutated human metastatic tumors with p63 activators: Tumor suppressor MiRNA miR-335, an activator of TAp63, suppresses the expression of MMP9 via down regulation of its target gene. This data suggests that miR-335, by suppressing the expression of its down steam target gene, it will suppress the activity of MMP9. Given that tumor suppressor p53 is mutated in more than 50% of different human cancers, this study suggests, for the first time, a therapeutic strategy as to how mutant p53 expressing human metastatic cancer can be cured by activating its un-mutated homologous proteins.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan,Treating p53-mutated human metastatic tumors with p63 activators: Tumor suppressor MiRNA miR-335, an activator of TAp63, suppresses the expression of MMP9 via down regulation of its target gene, 3/June/2014, 8.24 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation